A Phase 1 Adaptive Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Trial Profile

A Phase 1 Adaptive Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs ADCT 402 (Primary)
  • Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 28 Jun 2017 Planned number of patients changed from 60 to 135.
    • 16 Jun 2017 According to an ADC Therapeutics media release, further results are expected later this year.
    • 16 Jun 2017 According to an ADC Therapeutics media release, first clinical data from this trial has been presented at the 14th International Conference on Malignant Lymphoma (ICML) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top